SAN FRANCISCO, Sept. 21 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, announced today its participation in the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA from September 21-25. Volcano programming for TCT includes a first look at new study data, live case broadcasts, education opportunities, and demonstrations of Volcano's precision PCI guidance tools. Volcano will also host breakfast and evening symposiums highlighting the role of tools such as IVUS, VH((R)) IVUS, ChromaFlo((R)) and Fractional Flow Reserve (FFR), which are designed to address the known limitations of angiographic PCI guidance.
"Angiography alone is not enough and more and more clinical data continue to support that message," said Scott Huennekens, President and CEO of Volcano. "Many physicians attending the TCT believe that minimally invasive, catheter based therapies are the best solution for the vast majority of patients - in terms of reduced morbidity and increased patient comfort, convenience, safety and greater cost effectiveness. Yet, large clinical studies continue to call these catheter-based therapies into question. Our belief at Volcano is that a sole reliance on a less precise imaging tool like the angiogram is what is holding back the interventional field. We need to take advantage of more precise guidance tools such as IVUS and FFR if we expect to continue the progress that interventionalists have made in the past 30 years."
Clinical Trial Results
On Wednesday, September 23, at 12:15 PM the two-year results of the FFR vs. Angiography for Multi-Vessel Eval
|SOURCE Volcano Corporation|
Copyright©2009 PR Newswire.
All rights reserved